Patent ID: 11857565
Assignee: SEAGEN INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A

Claim 2:
3. The Ligand Drug Conjugate compound of claim 2, wherein:
(a) L-LB-A- comprises one of the structures of:, wherein the nitrogen, carbon, or sulfur atom indicated by #is from the Ligand Unit; and wherein the wavy line indicates the site of covalent attachment to the remainder of the Ligand Drug Conjugate compound; or
(b) each -LB-A- has the structure of:, wherein
the wavy line adjacent to AO indicates the site of covalent attachment to LO; and the other wavy line indicates the site of covalent attachment to a sulfur atom of a Ligand Unit;
AO is an optional second subunit of A;
[HE] is an optional Hydrolysis Enhancing Unit, which is a component provided by A or a first subunit thereof; and
BU is an acyclic Basic Unit moiety comprising a primary, secondary, or tertiary amine as the basic functional group; the dotted curved line is absent; and Ra2 is a substituted C1-C12 alkyl group; or
Ra2 and BU, together with the carbon atom to which both are attached, define a substituted or unsubstituted spiro C3-C20 heterocyclo Basic Unit moiety comprising an annular secondary or tertiary amine as the basic functional group,
wherein the basic amine of the Basic Unit is protonated, unprotonated, or suitably protected by a nitrogen protecting group; or
(c) [HE] is —C(═O)—, and -LB-A- has the structure of:, wherein AO is optional.